Ovarian Cancer Clinical Roundup
(Medscape Medical News) Oct 28, 2020 - New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommendation may change.
(Markets Insider) Oct 27, 2020 - Sumitomo Dainippon Pharma Oncology, Inc. today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in...
(Foundation Medicine) Oct 27, 2020 - Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.
The new indications are...
(Purdue University) Oct 22, 2020 - Scientists estimate that nearly 60% of all cancer patients do not respond effectively to chemotherapy treatments. Even worse – many of those same patients experience toxic and sometimes deadly side effects.
(ESMO Open) - 2020-10-01
(Cancer Res) - 2020-10-21
(Ann Oncol) - 2020-10-19
Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, and Dr. Jordan, Obstetrician/Gynecologist, Broward Health, discuss high-grade serous ovarian cancer recurrence
PARP inhibition continues to steal the spotlight in advanced ovarian cancer, even in the absence of pivotal trial data.
Findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 showed a significant benefit for PARP inhibition earlier in the cancer pathway, offering hope for more long-term survivors, while other treatment paradigms such as immunotherapy failed again to make headway against the disease.